Company: PHR
Filing Date: 2025-12-09
Form Type: 10-Q
Source: 0001412408-25-000132
Chunk: 131

Company: Phreesia, Inc.
Filing Date: 2025-12-09
Form: 10-Q
Item: Part I, Item 1
Chunk 131
---
 processed through our solutions increased $8.7 million to $85.7 million for the nine months ended October 31, 2025, as compared to $77.1 million for the nine months ended October 31, 2024, due to the addition of new healthcare services clients, which drove increases in patient visits and patient payments processed through our platform.

•Network solutions. Our revenue from life sciences companies and other organizations increased $15.9 million to $104.2 million for the nine months ended October 31, 2025, as compared to $88.4 million for the nine months ended October 31, 2024, due to an increase in engagement, education programs and deeper patient outreach among the existing programs.

43

Cost of revenue (excluding depreciation and amortization) Three months endedOctober 31, ($ in thousands)20252024$ Change% ChangeCost of revenue (excluding depreciation and amortization)$18,338 $17,854 $484 3 %

Cost of revenue (excluding depreciation and amortization) increased $0.5 million to $18.3 million for the three months ended October 31, 2025, as compared to $17.9 million for the three months ended October 31, 2024. The increase resulted primarily from a $2.3 million increase in other third-party costs, partially offset by a $1.8 million decrease in labor costs.

Stock compensation incurred related to cost of revenue was $1.0 million and $1.3 million for the three months ended October 31, 2025 and 2024, respectively.

 Nine months endedOctober 31, ($ in thousands)20252024$ Change% ChangeCost of revenue (excluding depreciation and amortization)$52,373 $49,720 $2,653 5 %

Cost of revenue (excluding depreciation and amortization) increased $2.7 million to $52.4 million for the nine months ended October 31, 2025, as compared to $49.7 million for the nine months ended October 31, 2024. The increase resulted primarily from a $8.1 million increase in other third-party costs, partially offset by a $5.4 million decrease in labor costs.

Stock compensation incurred related to cost of revenue was $3.0 million and $3.7 million for the nine months ended October 31, 2025 and 2024, respectively